Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience

Eur J Haematol. 2020 Jan;104(1):72-73. doi: 10.1111/ejh.13335. Epub 2019 Oct 16.

Authors

Douglas Tremblay¹, Alexander S Vogel², Erin Moshier³, Ronald Hoffman¹, Marina Kremyanskaya¹, Selena Zhou¹, Thomas Schiano², John Mascarenhas¹

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
² Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Department of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

No abstract available

Keywords: direct oral anti-coagulant; myeloproliferative; splanchnic vein; thrombosis.

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Follow-Up Studies
Hematologic Neoplasms / mortality*
Humans
Male
Middle Aged
Myeloproliferative Disorders / mortality*
Retrospective Studies
Survival Rate
Venous Thrombosis / etiology
Venous Thrombosis / mortality*

Grants and funding